Scandinavian Journal of Gastroenterology最新文献

Novelty in the gut: a review of the gastrointestinal manifestations of syphilis. 肠道中的新奇事物：梅毒胃肠道表现综述。

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2024-11-14 DOI: 10.1080/00365521.2024.2429676

Lefika Bathobakae, Joseph Russo, Rammy Bashir, Angela Vidreiro, Phenyo Phuu, Tyler Wilkinson, Nischal Sharma, Ruhin Yuridullah, Kamal Amer, Keith Siau

{"title":"Novelty in the gut: a review of the gastrointestinal manifestations of syphilis.","authors":"Lefika Bathobakae, Joseph Russo, Rammy Bashir, Angela Vidreiro, Phenyo Phuu, Tyler Wilkinson, Nischal Sharma, Ruhin Yuridullah, Kamal Amer, Keith Siau","doi":"10.1080/00365521.2024.2429676","DOIUrl":"https://doi.org/10.1080/00365521.2024.2429676","url":null,"abstract":"Syphilis is a systemic infection caused by the spirochete Treponema pallidum. It is transmitted during pregnancy or through sexual contact. Signs and symptoms vary depending on the clinical stage of the disease. Syphilis has been well-studied, and the introduction of penicillin has resulted in a decline in the number of new cases and deaths. Recently, however, there has been a surge in new cases in young people, especially those with human immunodeficiency virus (HIV). This epidemiological shift has been attributed to increased sexual activity, risky sexual behaviors, and immunodeficiency. There is a paucity of data on gastrointestinal (GI) manifestations of syphilis owing to its rarity and lack of physician awareness. T. pallidum can seed to any part of the GI tract, resulting in esophagitis, gastritis, hepatitis, pancreatitis, or proctocolitis. Depending on the affected part of the GI tract, syphilis can present with nausea, vomiting, painless esophageal ulcers, dysphagia, abdominal pain, weight loss due to early satiety, diarrhea, melena, hematochezia, dyschezia, or anorectal ulcers. Given its indolent clinical course and vague presentation, GI syphilis can mimic other GI disorders, which can delay diagnosis and treatment. A detailed medical history, physical examination, serological tests, and endoscopy can provide a definitive diagnosis. Syphilis and its GI complications are usually treated with long-acting intramuscular penicillin benzathine, and rarely with a 14-day course of intravenous penicillin. Herein, we describe the clinical features, etiopathogenesis, diagnosis, and treatment of GI syphilis. This primer should aid clinicians in timely diagnosis and treatment of various presentations of GI syphilis.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-8"},"PeriodicalIF":1.6,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142627392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High neutrophil-to-lymphocyte ratio at Helicobacter pylori eradication increases the risk of eradication failure and post-eradication gastric cancer. 根除幽门螺杆菌时中性粒细胞与淋巴细胞的比率过高会增加根除失败和根除后患胃癌的风险。

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2024-11-14 DOI: 10.1080/00365521.2024.2428280

Takeshi Yasuda, Nobuaki Yagi, Tatsushi Omatsu, Hiroaki Kitae, Yuki Nakahata, Yuriko Yasuda, Naoyuki Sakamoto, Akihiro Obora, Yoshiki Murakami, Takao Kojima

{"title":"High neutrophil-to-lymphocyte ratio at Helicobacter pylori eradication increases the risk of eradication failure and post-eradication gastric cancer.","authors":"Takeshi Yasuda, Nobuaki Yagi, Tatsushi Omatsu, Hiroaki Kitae, Yuki Nakahata, Yuriko Yasuda, Naoyuki Sakamoto, Akihiro Obora, Yoshiki Murakami, Takao Kojima","doi":"10.1080/00365521.2024.2428280","DOIUrl":"https://doi.org/10.1080/00365521.2024.2428280","url":null,"abstract":"Introduction: Vonoprazan has been known to have a high Helicobacter pylori (H. pylori) eradication rate since its launch in 2015. Yet, the risk factors for eradication failure and development of post-eradication gastric cancer (GC) using VPZ regimen remain unclear.Methods: This single-center cohort study included 934 consecutive patients who underwent H. pylori eradication using VPZ between February 2015 and June 2017 and were followed up for five years by the end of 2022. We examined several indicators of systemic immune, inflammatory, and nutritional status at the time of eradication to identify those indicators could predict eradication success, risk of post-eradication GC development, and long-term prognosis.Results: The successful eradication rates were 92.6% (intention-to-treat) and 98.7% (per-protocol). Multivariate analysis showed that only a high peripheral blood neutrophil-to-lymphocyte ratio (NLR) was significantly associated with eradication failure. The 5-year GC incidence rate was 1.67%, and all GCs were stage IA. The mean (standard deviation [SD]) time from eradication to diagnosis was 40.5 (6.1) months. Multivariate analysis showed that high NLR and history of GC and hypertension were significantly associated with GC development. Patients with elevated NLR post-eradication had a higher risk of newly developed GC. Twelve patients died during the study period, and a high NLR was associated with a significantly higher mortality rate.Conclusions: NLR has the potential to be a biomarker that predicts the failure of eradication and development of post-eradication GC. High NLR was also associated with poor long-term prognosis after H. pylori eradication.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-12"},"PeriodicalIF":1.6,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142627389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of an anti-inflammatory diet (AID) on maternal and neonatal health outcomes in pregnant Chinese patients with inflammatory bowel disease treated with infliximab (IFX). 抗炎饮食（AID）对接受英夫利昔单抗（IFX）治疗的中国炎症性肠病孕妇和新生儿健康结果的影响。

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2024-11-09 DOI: 10.1080/00365521.2024.2423828

Yong-Mei Ye, Mei-Hao Wei, Kai-Ni Lv, Xiao-Hui Xue, Rui Shen, Jing-Han Liu

{"title":"Effects of an anti-inflammatory diet (AID) on maternal and neonatal health outcomes in pregnant Chinese patients with inflammatory bowel disease treated with infliximab (IFX).","authors":"Yong-Mei Ye, Mei-Hao Wei, Kai-Ni Lv, Xiao-Hui Xue, Rui Shen, Jing-Han Liu","doi":"10.1080/00365521.2024.2423828","DOIUrl":"https://doi.org/10.1080/00365521.2024.2423828","url":null,"abstract":"Objective: This study aimed to evaluate the effects of an anti-inflammatory diet (AID) combined with Infliximab (IFX) therapy on maternal and neonatal health outcomes in pregnant Chinese patients with inflammatory bowel disease (IBD).Methods: IBD patients treated with steady IFX maintenance therapy at the time of conception were randomly assigned to either the IBD-AID group (n = 49), which received an anti-inflammatory diet intervention during the third trimester, or the habitual diet group (n = 49). Primary outcomes included assessments of disease activity, inflammatory markers, and neonatal health. Secondary outcomes included health-related quality of life (HRQoL) in patients and functional gastrointestinal disorders (FGIDs) in infants.Results: The IBD-AID intervention significantly reduced disease activity scores in IBD patients at 4 weeks post-intervention and 1 month postpartum compared to the habitual diet group, and also improved HRQoL. Serum C-reactive protein (CRP) and fecal calprotectin (FC) levels were significantly lower in the IBD-AID group at these times, with a trend towards lower levels at 6 months postpartum. Birth weight and Apgar scores were higher in the IBD-AID group but did not reach statistical significance. The incidence of at least one FGID in infants was significantly lower in the IBD-AID group (24.5%) compared to the habitual diet group (46.9%, p = 0.034).Conclusion: The IBD-AID intervention combined with IFX therapy significantly improved disease activity, inflammatory markers, and QoL in maternal IBD patients, and was associated with a lower incidence of FGIDs in infants, indicating benefits for both maternal and neonatal health.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-9"},"PeriodicalIF":1.6,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142627371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pyloric index, a new parameter: predicting perioperative prognosis in neonates with hypertrophic pyloric stenosis. 幽门指数，一个新参数：预测患有肥厚性幽门狭窄的新生儿围手术期的预后。

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2024-11-08 DOI: 10.1080/00365521.2024.2425982

Başak Kaya, Hasan Akduman, Dilek Dilli, Cem Geyik, Ayşe Karaman, Özlem Balcı, Hasibe Gökçe Çınar, Nurdan Dinlen Fettah, Ayşegül Zenciroğlu

{"title":"Pyloric index, a new parameter: predicting perioperative prognosis in neonates with hypertrophic pyloric stenosis.","authors":"Başak Kaya, Hasan Akduman, Dilek Dilli, Cem Geyik, Ayşe Karaman, Özlem Balcı, Hasibe Gökçe Çınar, Nurdan Dinlen Fettah, Ayşegül Zenciroğlu","doi":"10.1080/00365521.2024.2425982","DOIUrl":"https://doi.org/10.1080/00365521.2024.2425982","url":null,"abstract":"Purpose: Delays in the diagnosis and treatment of infantile hypertrophic pyloric stenosis (IHPS) may lead to laboratory and clinical decompensation in infants. The aim of this study was to determine whether pyloric measurement parameters can be effectively used in the clinical prognosis of IHPS by evaluating the relationship between pyloric dimensions on ultrasonographic evaluation at the time of presentation and clinical and laboratory parameters in infants with pyloric stenosis.Methods: A retrospective observational study was conducted on 122 infants who were followed up with the diagnosis of IHPS in our neonatal clinic and operated on by a pediatric surgeon between January 2005 and December 2020.Results: The mean pyloric dimensions of the infants were pyloric length 20 mm (17-22), pyloric thickness 5 mm (4-5.8), and pyloric index 96.5 (72.2-124). Babies with preoperative laboratory values of hypokalemia, hypochloremia and metabolic alkalosis had statistically higher pyloric thickness >5 mm (4.1-6) and pyloric index >100 (86-130) parameters.Conclusion: Pyloric thickness and pyloric index parameters can predict clinical prognosis in babies diagnosed with IHPS in the perioperative period.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-5"},"PeriodicalIF":1.6,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Forty years of successful national research collaboration in liver disease - the Swedish experience. 四十年成功的国家肝病研究合作--瑞典的经验。

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2024-11-01 DOI: 10.1080/00365521.2024.2421824

Annika Bergquist, Mattias Ekstedt, Hannes Hagström, Gunnar Järnerot, Stefan Lindgren, Emma Nilsson, Nils Nyhlin, Fredrik Rorsman, Per Stål, Mårten Werner, Stergios Kechagias

{"title":"Forty years of successful national research collaboration in liver disease - the Swedish experience.","authors":"Annika Bergquist, Mattias Ekstedt, Hannes Hagström, Gunnar Järnerot, Stefan Lindgren, Emma Nilsson, Nils Nyhlin, Fredrik Rorsman, Per Stål, Mårten Werner, Stergios Kechagias","doi":"10.1080/00365521.2024.2421824","DOIUrl":"https://doi.org/10.1080/00365521.2024.2421824","url":null,"abstract":"Aim: Sweden has historically provided a fruitful arena for research in clinical medicine. We here share 40 years of experience of collaboration in the Swedish hepatology research group (SWEHEP) (https://www.swehep.se).Methods: We describe the way the Swedish hepatology pioneers started the group and how the network continuously developed over the years. Successful projects such as thorough studies of natural history and various clinical aspects of autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, and steatosis are described.Results: Over the years, more than 80 publications have been published by the group. A summary of new and ongoing research programs includes the randomized placebo-controlled trial of simvastatin in PSC (PiSCATIN), the prospective BIGMAP (Biochemical and genetic markers for the assessment and prognostication of liver cirrhosis) initiative in patients with liver cirrhosis, and the DETECT-HCC, a prospective multicenter cohort study comparing abbreviated MRI and ultrasound for surveillance of hepatocellular carcinoma every six months over two years. The group philosophy, success factors for the longstanding collaboration as well as experience of failures are shared.Conclusion: The success of hepatology research in Sweden is based on longstanding collaboration over generations of hepatologists, where everyone contributes, regular research meetings, mutual trust, and perseverance.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-8"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

'Does this fecal microbiota transplant work?' Quality assurance of capsule based fecal microbiota transplant production. 粪便微生物群移植有用吗？基于胶囊的粪便微生物群移植生产的质量保证。

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2024-11-01 Epub Date: 2024-10-01 DOI: 10.1080/00365521.2024.2401460

Emil Ainsworth Jochumsen, Maja Skov Kragsnaes, Anna Christine Nilsson, Kristina Fruerlund Rasmussen, Torkell Ellingsen, Mie Agerbaek Juul, Jens Kjeldsen, Dorte Kinggaard Holm

{"title":"'Does this fecal microbiota transplant work?' Quality assurance of capsule based fecal microbiota transplant production.","authors":"Emil Ainsworth Jochumsen, Maja Skov Kragsnaes, Anna Christine Nilsson, Kristina Fruerlund Rasmussen, Torkell Ellingsen, Mie Agerbaek Juul, Jens Kjeldsen, Dorte Kinggaard Holm","doi":"10.1080/00365521.2024.2401460","DOIUrl":"10.1080/00365521.2024.2401460","url":null,"abstract":"Background: Fecal Microbiota Transplant (FMT) is an effective treatment for recurring Clostridioides Difficile Infections (rCDI). FMT administered via oral capsules (caFMT) offers several practical advantages to conventional liquid FMT. We began using caFMT in 2021 imported from an external institution. Based on similar production methods, we began our own caFMT production in 2022. We aimed to evaluate the quality of our caFMT.Study design and methods: We created a database of all FMT treatments (n = 180) provided by our institution. Quality of all FMT was evaluated by treatment success rates. We compared our caFMT to the imported caFMT.Results: Our caFMT yielded similar success rates compared to that of the imported caFMT, 65% (CI 95% 58-72%) and 72% (CI 95% 66-79%) respectively. FMT administered via colonoscopy had a significantly higher success rate, 79% (CI 95% 73-85%) than own our caFMT and other routes of administration. The combined success rate of treatments increased notably for all routes of administration when repeating FMT after prior failure.Discussion: The fact that our caFMT compared similarly to the imported caFMT was viewed as a success in terms of quality assurance. Our caFMT had a slightly lower success rates compared to data from other studies, but could be affected by several other factors than our FMT-production methods. A lower success rate of caFMT compared to FMT via colonoscopy is acceptable due to the practical advantages offed by caFMT. Our study serves as a practical example, proving that of the standardization of caFMT production is indeed viable.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1234-1239"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142353058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obstructive sleep apnoea is independently associated with non-alcoholic fatty pancreatic disease. 阻塞性睡眠呼吸暂停与非酒精性脂肪性胰腺疾病密切相关。

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2024-11-01 Epub Date: 2024-09-26 DOI: 10.1080/00365521.2024.2406559

Jiaojiao Lin, Han Wang, Xiaoyang Chen, Lina Han, Zhibin Huang, Guorong Lyu, Shilin Li

{"title":"Obstructive sleep apnoea is independently associated with non-alcoholic fatty pancreatic disease.","authors":"Jiaojiao Lin, Han Wang, Xiaoyang Chen, Lina Han, Zhibin Huang, Guorong Lyu, Shilin Li","doi":"10.1080/00365521.2024.2406559","DOIUrl":"10.1080/00365521.2024.2406559","url":null,"abstract":"Purpose: This study investigated the prevalence of non-alcoholic fatty pancreatic disease (NAFPD) in patients with obstructive sleep apnoea (OSA) and analysed the correlation between them.Materials and methods: Patients who underwent polysomnography and modified abdominal ultrasound examinations were continuously enrolled and divided into OSA and control groups. The OSA group was further divided into NAFPD and non-NAFPD groups. Differences in various indicators were compared. Binary logistic regression analyses were conducted to identify factors influencing NAFPD.Results: A total of 210 participants were included in the study, including 178 in the OSA group and 32 in the control group. The prevalence of NAFPD, weight, body mass index (BMI), and other indicators were significantly higher in the OSA group than that in the control group (p < 0.05). The above indices, prevalence of hypertension and metabolic associated steatotic liver disease (MASLD), and severity of sleep apnoea were higher in the NAFPD group than that in the non-NAFPD group (p < 0.05). Binary logistic regression analysis showed a 4.4% increased risk of NAFPD for each unit increase in apnea-hypopnea index (AHI) after adjusting for BMI and hypertension.Conclusion: The prevalence of NAFPD was higher in the OSA group than that in the control group, and chronic intermittent hypoxia was strongly associated with pancreatic fat infiltration; AHI, BMI, and hypertension were independent risk factors for NAFPD. The NAFPD group had a higher prevalence of obesity and some other diseases.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1252-1258"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142353059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The risk of cholangiocarcinoma in patients with MASLD is not increased compared to the general population. 与普通人群相比，MASLD 患者罹患胆管癌的风险并没有增加。

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2024-11-01 Epub Date: 2024-10-09 DOI: 10.1080/00365521.2024.2412735

Christina Villard, Linnea Widman, Ernesto Sparrelid, Annika Bergquist, Hannes Hagström

{"title":"The risk of cholangiocarcinoma in patients with MASLD is not increased compared to the general population.","authors":"Christina Villard, Linnea Widman, Ernesto Sparrelid, Annika Bergquist, Hannes Hagström","doi":"10.1080/00365521.2024.2412735","DOIUrl":"10.1080/00365521.2024.2412735","url":null,"abstract":"Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in prevalence globally. MASLD is associated with an increased rate of comorbidities, including cardiovascular disease, liver cirrhosis, and hepatocellular carcinoma (HCC). While the link between MASLD and HCC is well known, the potential association with biliary tract cancer, including cholangiocarcinoma (CCA) and gallbladder cancer (GBC), is less certain. To evaluate whether individuals with MASLD are at increased risk of developing CCA compared to the general population, we performed a nationwide cohort study investigating the longitudinal association between MASLD and CCA.Methods: A retrospective cohort study was performed including all patients ≥18 years of age, diagnosed with MASLD, from 1st of January 1987 to 31st of December 2020, through the Swedish National Patient Register. For each patient with MASLD, ten individuals, matched to the MASLD patient on year of diagnosis, age, sex, and municipality were selected as reference individuals. The international Classification of Diseases (ICD) codes were used to define MASLD and incident CCA. Incidence rates were calculated, and regression analyses were performed.Results: Out of the 11,940 exposed patients with MASLD, 11 developed CCA (0.1%) out of whom three were diagnosed with iCCA (0.03%), during a median follow-up time of five years. Out of 112,537 reference individuals, 62 were diagnosed with CCA (0.3%), out of whom 15 were diagnosed with iCCA (0.01%). The rate of GBC was not higher compared to the reference population.Conclusion: This large cohort study found a low incidence of CCA in patients with MASLD, comparable to the general population which can reassure clinicians and patients that no specific vigilance for CCA should be considered in MASLD patients at present.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1249-1251"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mortality and rate of hospitalization stratified by patients' BMI in a colonoscopy screening - a cross sectional analysis of data from Polish Colonoscopy Screening Platform. 结肠镜筛查中按患者体重指数分层的死亡率和住院率--对波兰结肠镜筛查平台数据的横断面分析。

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2024-11-01 Epub Date: 2024-10-04 DOI: 10.1080/00365521.2024.2410795

Piotr Spychalski, Paulina Wieszczy, Katarzyna Połomska, Jarek Kobiela, Jaroslaw Regula, Michal F Kaminski, Nastazja Pilonis

{"title":"Mortality and rate of hospitalization stratified by patients' BMI in a colonoscopy screening - a cross sectional analysis of data from Polish Colonoscopy Screening Platform.","authors":"Piotr Spychalski, Paulina Wieszczy, Katarzyna Połomska, Jarek Kobiela, Jaroslaw Regula, Michal F Kaminski, Nastazja Pilonis","doi":"10.1080/00365521.2024.2410795","DOIUrl":"10.1080/00365521.2024.2410795","url":null,"abstract":"Background: Currently, it remains unknown whether there is an association between body mass index (BMI) and complications during screening colonoscopy; hence, it remains unclear whether BMI should be considered a risk factor in pre-procedural assessments. The aim of this study was to compare mortality and unplanned hospitalization rates before and after colonoscopy stratified by patients' BMI.Material and methods: This was a retrospective cohort study of individuals who underwent screening colonoscopy as part of the Polish Colonoscopy Screening Program (PCSP). The included individuals were followed up for mortality and hospitalization episodes from 42 days prior to colonoscopy to 30 days after the procedure. Rates for the endpoints were calculated, compared, and adjusted for available data. Weighted averages of stratum-specific rates were calculated. Additional subanalyses were performed for sex and procedure type (screening colonoscopy without biopsy, colonoscopy with biopsy, or colonoscopy with polypectomy).Results: A total of 55390 individuals who underwent colonoscopy between years 2012-2015 were included. Obese individuals had significantly more hospitalizations than non-obese patients (1.94% versus 0%, p = .038). Analysis of adjusted hospitalization rates stratified by sex revealed that obese males had significantly higher related hospitalizations' rates before or after and after colonoscopy. Unadjusted and adjusted mortality rates after screening colonoscopy did not reveal significant differences between BMI categories.Conclusions: Overweight and obesity are not clinically relevant risk factors for mortality and hospitalization six weeks before or 30 days after screening colonoscopy. Obese males may be more likely to require hospital care after colonoscopy.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1259-1264"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eradication rate and safety of vonoprazan-amoxicillin dual therapy for helicobacter pylori eradication: a randomized controlled trial. 根除幽门螺旋杆菌的沃诺普拉赞-阿莫西林双重疗法的根除率和安全性：随机对照试验。

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2024-11-01 Epub Date: 2024-09-22 DOI: 10.1080/00365521.2024.2407898

Guoping Jiang, Mengzhao Luo, Peifen Zheng, Yanqun Cong, Yuliang Feng, Feng Zhou

{"title":"Eradication rate and safety of vonoprazan-amoxicillin dual therapy for helicobacter pylori eradication: a randomized controlled trial.","authors":"Guoping Jiang, Mengzhao Luo, Peifen Zheng, Yanqun Cong, Yuliang Feng, Feng Zhou","doi":"10.1080/00365521.2024.2407898","DOIUrl":"10.1080/00365521.2024.2407898","url":null,"abstract":"Background: Helicobacter pylori (H. pylori), prevalent in developing regions, is a key factor in gastrointestinal diseases. Despite the common use of bismuth-based quadruple therapy, its drawbacks have prompted the search for alternatives. Recently, vonoprazan, a novel acid suppressant, has shown promise in combination with antibiotics as a dual therapy for H. pylori eradication. This study aimed to assess the therapeutic outcomes and adverse events of vonoprazan-amoxicillin dual therapy compared to quadruple therapy.Methods: A randomized controlled trial (RCT) enrolled H. pylori-infected patients at Zhejiang Hospital. Participants were randomly assigned to dual and quadruple therapy groups. The primary endpoints were H. pylori eradication and adverse events.Results: Of the 400 patients studied from April 2022 to June 2023, In the intention-to-treat (ITT) analysis, the eradication rates of H. pylori in vonoprazan-amoxicillin dual therapy group and quadruple therapy group were 94.0% and 87.0%, respectively, p = 0.017. In the per-protocol (PP) analysis were 97.9% and 93.0%, p = 0.022. Additionally, the dual therapy group had a significantly lower incidence of adverse events (19%) compared to the quadruple therapy group (53%) (p < 0.001).Conclusion: Vonoprazan-amoxicillin dual therapy demonstrates superior eradication efficacy and reduced adverse events compared to quadruple therapy in H. pylori-infected patients, suggesting its potential for clinical application and promotion.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1229-1233"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142294383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0